Healthcare / Medical DevicesShenzhen
$5.68
+0.26 (+4.80%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-304.9M · quality 54.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-27.8%
↓Gross Margin
35.1%
↓Debt/Equity
0.26
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-38.2%
FCF CAGR
—
FCF margin
-7.1%
FCF / Net income
0.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.64B · net income $-732.1M · FCF $-116.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.64B | $1.64B | $1.76B | $2.43B | $6.97B |
| Net Income | $-732.1M | $-732.1M | $-640.6M | $-234.0M | $971.6M |
| EBITDA | $-550.0M | $-550.0M | $-446.2M | $74.1M | $2.32B |
| EPS | -1.42 | -1.42 | -1.27 | -0.46 | 1.82 |
| Gross Margin | 35.1% | 35.1% | 36.8% | 42.8% | 52.6% |
| Operating Margin | -20.6% | -20.6% | -17.1% | -0.3% | 32.9% |
| Net Margin | -44.6% | -44.6% | -36.4% | -9.6% | 13.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.26 | 0.26 | 0.14 | 0.22 | 0.18 |
| Current Ratio | 1.77 | 1.77 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-116.9M | $-116.9M | $-304.9M | $-805.8M | $1.73B |
| Returns | |||||
| ROE | -27.8% | -27.8% | -19.1% | -5.6% | 20.2% |
| Valuation | |||||
| P/E | — | — | — | — | 6.80 |
| EV/EBITDA | — | — | — | 62.48 | 1.72 |
| P/B | 1.11 | 1.11 | 0.89 | 1.28 | 1.37 |
| Growth & Yield | |||||
| Revenue Growth | -6.6% | -6.6% | -27.5% | -65.2% | — |
| EPS Growth | -12.2% | -12.2% | -178.8% | -125.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-5.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.27 → -1.42
Residual
-5.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.